Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J's Revamped R&D Will Release First Drug In 2004, Diabetic Likely Choice

Executive Summary

Johnson & Johnson's re-engineered research and development program will release its first product in 2004, most likely in the diabetes area, R&D Pharmaceuticals Chairman Per Peterson, MD/PhD, indicated.

You may also be interested in...



J&J Zarnestra R&D Overseen By Ortho Oncology/HIV Group, Headed By Mattes

Clinical development of Johnson & Johnson's farnesyl transferase inhibitor Zarnestra will be overseen by the company's tentatively named Ortho Oncology & Specialty Therapeutics business unit

J&J Zarnestra R&D Overseen By Ortho Oncology/HIV Group, Headed By Mattes

Clinical development of Johnson & Johnson's farnesyl transferase inhibitor Zarnestra will be overseen by the company's tentatively named Ortho Oncology & Specialty Therapeutics business unit

Alza Delivery Technologies Reduce Drug Enhancement Costs To $80 Mil.

Alza drug delivery technologies reduce the cost of developing an enhanced version of an already-marketed drug to $70 mil.-$80 mil., Alza Chairman Sam Saks, MD, said during Johnson & Johnson's business review Sept. 23

Related Content

UsernamePublicRestriction

Register

PS037994

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel